InVivo Therapeutics Holding Corp has appointed Steven McAllister as its chief financial officer, effective immediately. A company news release reports that McAllister has been serving as the Cambridge, Mass-based organization’s CEO since December of 2013.

Before joining InVivo, McAllister served as vice president, Finance and Administration for Biomet Spine and Bone Healing Technologies from 2007 to 2013. During his tenure, McAllister was responsible for all accounting, finance, IT, facilities, and insurance operations activities in addition to leading the company’s strategic planning initiatives.

Prior to Biomet, the news release notes that McAllister spent 8 years with Johnson & Johnson’s Medical Device and Diagnostics Group, where his role was director of Finance for the worldwide spine business, and director of Finance, Worldwide Operations, for Global Orthopedics. Additionally, McAllister worked in several capacities in Pfizer’s medical device business, which was sold to Stryker in 1998. McAllister received his BS in Accounting from Fairleigh Dickson University.

In the release, Mark Perrin, InVivo’s chief executive officer, states that McAllister brings “a wealth of experience in financial management. I value the contributions he has made during this transitional period and I am pleased to have him as part of the leadership team.”

InVivo Therapeutics Holding Corp is a biomaterials company with technologies engineered to for drug delivery with a focus on treatment of spinal cord injuries.

Source: InVivo Therapeutics Holding Corp